Ventyx Biosciences
Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
Company Facts
- Headquarters
- San Diego
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- public
- Employees
- c_00101_00250
- Funding Stage
- m_and_a
- Total Funding
- $468,600,000
- Last Funding Type
- post_ipo_equity
- Last Funding Date
- 2024-09-23
- Website
- ventyxbio.com
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical, Therapeutics
Social Links
Canonical: https://fsome.com/organization/ventyx-biosciences-14039 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.